{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:13:13Z","timestamp":1784628793018,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.sapharm.2024.06.008","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T23:50:03Z","timestamp":1718841003000},"page":"934-939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs)"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1051-3240","authenticated-orcid":false,"given":"Zaheer-Ud-Din","family":"Babar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2024.06.008_bib1","unstructured":"https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-global-use-of-medicines-2023."},{"key":"10.1016\/j.sapharm.2024.06.008_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40545-022-00413-3","article-title":"Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan","volume":"15","author":"Babar","year":"2022","journal-title":"J. Pharm. Pol. Pract."},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","article-title":"How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries","volume":"15","author":"Vogler","year":"2017","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.sapharm.2024.06.008_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.phrs.2016.05.022","article-title":"Balancing access to medicines and sustainability in Europe: an analysis from the network of competent authorities on pricing and reimbursement (CAPR)","volume":"111","author":"Pani","year":"2016","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14737167.2019.1527221","article-title":"Cross-national drug price comparisons with economic weights in external reference pricing in Germany","volume":"19","author":"Mahlich","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.sapharm.2024.06.008_bib6","doi-asserted-by":"crossref","DOI":"10.18773\/austprescr.2014.059","article-title":"Differences in Australian and New Zealand medicines funding policies","author":"Babar","year":"2014","journal-title":"Aust Prescr"},{"key":"10.1016\/j.sapharm.2024.06.008_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2441","article-title":"How New Zealand has contained expenditure on drugs","volume":"340","author":"Cumming","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.sapharm.2024.06.008_bib8","unstructured":"Access to medicines: making market forces serve the poor.https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/fair-price\/chapter-medicines.pdf?sfvrsn=adcffc8f_4&download=true."},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/jphs.12304","article-title":"Pharmaceutical pricing policies in Qatar and Lebanon: narrative review and document analysis","volume":"10","author":"Abdel Rida","year":"2019","journal-title":"J Pharmaceut Health Serv Res"},{"key":"10.1016\/j.sapharm.2024.06.008_bib10","article-title":"Policy options for pharmaceutical pricing and purchasing issues for low-and middle-income countries","author":"Nguyen","year":"2014","journal-title":"Health Pol Plann"},{"issue":"12","key":"10.1016\/j.sapharm.2024.06.008_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2213-8587(21)00240-0","article-title":"Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis","volume":"9","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.sapharm.2024.06.008_bib12","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1016\/S2214-109X(22)00330-8","article-title":"The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review","volume":"10","author":"Stolbrink","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.sapharm.2024.06.008_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1196\/annals.1425.011","article-title":"Poverty and access to health care in developing countries","volume":"1136","author":"Peters","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.sapharm.2024.06.008_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/heapol\/czs108","article-title":"Access to medicines from a health system perspective","volume":"28","author":"Bigdeli","year":"2013","journal-title":"Health Pol Plann"},{"key":"10.1016\/j.sapharm.2024.06.008_bib16","series-title":"Equitable Access to Essential Medicines : A Framework for Collective Action","year":"2004"},{"key":"10.1016\/j.sapharm.2024.06.008_bib17","unstructured":"https:\/\/dictionary.cambridge.org\/dictionary\/english\/effective."},{"key":"10.1016\/j.sapharm.2024.06.008_bib18","first-page":"462","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature","volume":"9","author":"Phyllis","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.sapharm.2024.06.008_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/jphs.12191","article-title":"A systematic review of pharmaceutical pricing policies in developing countries","author":"Abdel Rida","year":"2017","journal-title":"J Pharmaceut Health Serv Res"},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jphsr\/rmac027","article-title":"Analysis of cancer drug prices: a narrative review of literature","volume":"13","author":"Shazad","year":"2022","journal-title":"J Pharmaceut Health Serv Res"},{"key":"10.1016\/j.sapharm.2024.06.008_bib21","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3389\/fphar.2019.01375","article-title":"The availability, pricing and affordability of essential diabetes medicines in 17 low-, middle- and high-income countries","volume":"10","author":"Babar","year":"2019","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.sapharm.2024.06.008_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40273-013-0095-9","article-title":"The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries","volume":"31","author":"Babar","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12913-021-06627-6","article-title":"Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa","volume":"21","author":"Mattila","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","article-title":"Oncology medicines in European countries, Australia and New Zealand: a cross-country price comparison study","volume":"17","author":"Vogler","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.sapharm.2024.06.008_bib25","article-title":"Access to medicines - a systematic review of the literature [published online ahead of print, 2019 Dec 11]","volume":"S1551\u20137411","author":"Abbas","year":"2019","journal-title":"Res Soc Adm Pharm"},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.sapharm.2018.04.006","article-title":"Patient access to medicines in two countries with similar health systems and differing medicines policies: implications from a comprehensive literature review","volume":"15","author":"Babar","year":"2018","journal-title":"Res Soc Adm Pharm"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib27","first-page":"1","article-title":"Mapping the pharmaceutical situation in your country: first things first","volume":"2","author":"Babar","year":"2009","journal-title":"South. Med. Rev."},{"issue":"12","key":"10.1016\/j.sapharm.2024.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006471","article-title":"The effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centres: evidence from a longitudinal study","volume":"4","author":"Zhang","year":"2014","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.sapharm.2024.06.008_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2471\/BLT.22.287936","article-title":"National medicines policy development, Saudi Arabia","volume":"100","author":"Almoteiry","year":"2022","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.18773\/austprescr.2020.007","article-title":"National medicines policy 2.0: a vision for the future","volume":"43","author":"McLachlan","year":"2020","journal-title":"Aust Prescr"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2052-3211-6-5","article-title":"National medicines policies \u2013 a review of the evolution and development processes","volume":"6","author":"Hoebert","year":"2013","journal-title":"J. Pharm. Pol. Pract."},{"key":"10.1016\/j.sapharm.2024.06.008_bib32","unstructured":"WHO. Measuring medicine prices, availability, affordability and price components second ed.: http:\/\/haiweb.org\/publication\/measuring-medicine-pricesavailability-affordability-and-price-components-2nd-ed."},{"key":"10.1016\/j.sapharm.2024.06.008_bib33","article-title":"International drug price indicator guide","year":"2017","journal-title":"Manag. Sci. Health"},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040082","article-title":"Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia","volume":"4","author":"Babar","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.sapharm.2024.06.008_bib35","doi-asserted-by":"crossref","first-page":"104919","DOI":"10.1016\/j.healthpol.2023.104919","article-title":"A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain","volume":"138","author":"Joosse","year":"2023","journal-title":"Health Pol"},{"key":"10.1016\/j.sapharm.2024.06.008_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40545-017-0104-z","article-title":"Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review","volume":"10","author":"Konduri","year":"2017","journal-title":"J. Pharm. Pol. Pract."},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.sapharm.2022.07.010","article-title":"A comparative analysis of pharmaceutical workforce development needs across the commonwealth","volume":"19","author":"Bates","year":"2023","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.sapharm.2024.06.008_bib38","series-title":"WHO Guideline on Country Pharmaceutical Pricing Policies","year":"2020"},{"key":"10.1016\/j.sapharm.2024.06.008_bib39","series-title":"WHO Guideline on Country Pharmaceutical Pricing Policies","year":"2013"},{"key":"10.1016\/j.sapharm.2024.06.008_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2021.100045","article-title":"Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability, and generic penetration","volume":"2","author":"Kamphuis","year":"2021","journal-title":"Health Policy Open"},{"key":"10.1016\/j.sapharm.2024.06.008_bib41","series-title":"Medicine Price Surveys, Analyses and Comparisons: Evidence and Methodology Guidance","author":"Vogler","year":"2018"},{"key":"10.1016\/j.sapharm.2024.06.008_bib42","series-title":"Medicine Price Surveys, Analyses and Comparisons: Evidence, Methodology and Guidance","article-title":"Assessment of external price referencing and alternative policies","author":"Vogler","year":"2019"},{"key":"10.1016\/j.sapharm.2024.06.008_bib43","series-title":"Pharmaceutical Policy in Countries with Developing Healthcare Systems [Internet]","article-title":"Pharmaceutical policy in Jordan","author":"El-Dahiyat","year":"2017"},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/erp.11.90","article-title":"Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi","volume":"12","author":"Abuelkhair","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"suppl 1","key":"10.1016\/j.sapharm.2024.06.008_bib45","article-title":"Impact of generic price linkage system and reference price system on prices of pharmaceuticals\u2013comparison of Austria and Finland","volume":"8","author":"Martikainen","year":"2015","journal-title":"J. Pharm. Pol. Pract."},{"issue":"12","key":"10.1016\/j.sapharm.2024.06.008_bib46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2165\/11584890-000000000-00000","article-title":"Is there a role for pharmacoeconomics in developing countries?","volume":"28","author":"Babar","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.sapharm.2024.06.008_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.healthpol.2021.12.007","article-title":"How value-based policy interventions influence price negotiations for new medicines: an experimental approach and initial evidence","volume":"126","author":"Wettstein","year":"2022","journal-title":"Health Pol"},{"key":"10.1016\/j.sapharm.2024.06.008_bib48","unstructured":"Brand Premium Policy, The Pharmaceutical Benefit Scheme. https:\/\/www.pbs.gov.au\/browse\/brand-premium."},{"issue":"1","key":"10.1016\/j.sapharm.2024.06.008_bib49","article-title":"Developing Nepal's medicines pricing policy: evidence synthesis and stakeholders' consultation","volume":"17","author":"Babar","year":"2024","journal-title":"J. Pharmaceut. Pol. Pract."},{"key":"10.1016\/j.sapharm.2024.06.008_bib50","unstructured":"Zangpo T. Pharmaceutical Pricing Situation. Medical Product Division, Bhutan Food and Drug Authority, Thimphu Bhutan 31st October 2023."},{"key":"10.1016\/j.sapharm.2024.06.008_bib51","unstructured":"Cabinet approves drug price. eregulation.https:\/\/tribune.com.pk\/story\/2455673\/cabinet-approves-drug-price-deregulation, 6th feb 2024.(Accessed 28th February 2024)."},{"key":"10.1016\/j.sapharm.2024.06.008_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40545-023-00643-z","article-title":"Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations","volume":"16","author":"Butani","year":"2023","journal-title":"J. Pharm. Pol. Pract."},{"issue":"4","key":"10.1016\/j.sapharm.2024.06.008_bib53","first-page":"32","article-title":"Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in Malaysia","volume":"18","author":"Dranitsaris","year":"2011","journal-title":"Malays J Med Sci"},{"key":"10.1016\/j.sapharm.2024.06.008_bib54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1108\/10610420810916399","article-title":"Fair price: research outside marketing","volume":"17","author":"Maxwell","year":"2008","journal-title":"J Prod Brand Manag"},{"key":"10.1016\/j.sapharm.2024.06.008_bib55","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1086\/346244","article-title":"Consumer perceptions of price (un)fairness","volume":"29","author":"Bolton","year":"2003","journal-title":"J Consum Res"},{"key":"10.1016\/j.sapharm.2024.06.008_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5235\/174410511795887606","article-title":"Excessive prices within EU competition law","volume":"7","author":"Hou","year":"2011","journal-title":"J. Eur. Compet."},{"key":"10.1016\/j.sapharm.2024.06.008_bib57","doi-asserted-by":"crossref","first-page":"l4726","DOI":"10.1136\/bmj.l4726","article-title":"Defining the concept of fair pricing for medicines","volume":"368","author":"Moon","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jphs.12061","article-title":"Differential pricing of pharmaceuticals: a bibliometric review of the literature","volume":"5","author":"Babar","year":"2014","journal-title":"J Pharmaceut Health Serv Res"},{"key":"10.1016\/j.sapharm.2024.06.008_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/gatesopenres.13110.3","article-title":"Value-based tiered pricing for universal health coverage: an idea worth revisiting","volume":"4","author":"Chalkidou","year":"2020","journal-title":"Gates Open Res"},{"issue":"3","key":"10.1016\/j.sapharm.2024.06.008_bib60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hec.3021","article-title":"Value-based differential pricing: efficient prices for drugs in a global context","volume":"24","author":"Danzon","year":"2015","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.sapharm.2024.06.008_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.healthpol.2014.12.004","article-title":"Medicine price awareness in chronic patients in Belgium","volume":"119","author":"Fraeyman","year":"2015","journal-title":"Health Pol"},{"key":"10.1016\/j.sapharm.2024.06.008_bib62","article-title":"South Africa paying more than double EU price for Oxford vaccine","author":"Sullivan","year":"2021","journal-title":"Guardian"},{"key":"10.1016\/j.sapharm.2024.06.008_bib63","article-title":"European governments should align medicines pricing practices with global transparency norms and legal principles","volume":"16","author":"Perehudoff","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.sapharm.2024.06.008_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2022.11.002","article-title":"Evidence on the effectiveness of policies promoting price transparency - a systematic review","volume":"134","author":"Joosse","year":"2023","journal-title":"Health Pol"},{"key":"10.1016\/j.sapharm.2024.06.008_bib65","series-title":"Health Policy","first-page":"534","article-title":"Pharmaceutical net price transparency across European markets: insights from a multi-agent simulation model","volume":"126","author":"Riccaboni","year":"2022"},{"key":"10.1016\/j.sapharm.2024.06.008_bib66","series-title":"European Observatory on Health Systems","article-title":"What are the implications of policies increasing transparency of prices paid for pharmaceuticals? A primer for understanding the policy perspective in light of the empirical evidence Policy Brief 45","author":"Webb","year":"2022"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741124001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741124001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T21:49:36Z","timestamp":1722462576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741124001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1551741124001992"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2024.06.008","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs)","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2024.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}